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Abstract
OBJECTIVE: Metastatic spinal diseases are common health problems and there is no
consensus on the appropriate  treatment  of metastases  in several conditions.  Using clinical
measures (e.g., survival time and functional status), prognosis prediction systems advise on
the appropriate interventions. The aim of this article is to assess and compare 4 widely used
scoring systems (revised Tokuhashi, Tomita, van der Linden, and modified Bauer scores) on a
single-center cohort.
METHODS:  A retrospective  study  was  designed  of  329  patients  who  were  subjected  to
surgery because of meta-static spinal diseases. Subpopulations according to the classifications
of the 4 scoring systems were identified. The overall survival was calculated with the Kaplan-
Meier formula. The difference between the survival curves of subpopulations was analyzed
with log-rank tests. The consistency rates for the 4 scoring systems are calculated as well.
RESULTS: The follow-up period was 8 years. The median survival time was 222 days. The
overall survival of prognostic categories in 3 scoring systems was significantly different from
each other, but we found no differences between the categories of the van der Linden system.
In this cohort, the revised Tokuhashi system gave the best approximation for survival, with a
mean predictive capability 60.5%.
CONCLUSIONS: The evaluation  of 4 standard scoring systems showed that  3 were self-
consistent, although none of systems was able to predict the survival in our cohort. Based on
the predictive capability, the revised Tokuhashi system may provide the best predictions with
careful examination of individual cases.
Introduction
The  vertebral  column is  the  third  most  common  site  for  metastasis  after  pulmonary  and
hepatic secondary lesions and the most common site for skeletal lesions. [1,2] It affects 7% of
patients with oncologic diseases. [3] Symptoms caused by tumors could be pain or motoric or
sensory deficits  caused by spinal cord or nerve root compression. [4-7] Optimal treatment
should take into account the patient’s general condition and life expectancy. Patients expected
to have long survival benefit from invasive surgical treatment or from high-dosage radiation
therapy or from a combination of these 2 treatments. In contrast, patients expected to have
shorter survival because of their poor general condition may benefit from more conservative
solutions (low-dosage radiation therapy, palliative or minimally invasive surgical options, or
supportive care). [4,8-10]
To make evidence-based choices for optimal care, several prognosis predicting systems have
been created  for  treatment  of  metastatic  spinal  tumors.  [11]  These  systems combine  risk
factors with different weights and classify patients into different prognostic groups. For each
prognosis category, a treatment is proposed based on the predicted survival. The aim of this
article is to analyze 4 prognostic scoring systems of patients with spinal metastasis. These
scoring systems are used in  spinal  neurosurgical  practice  to  determine  the  best  treatment
choices in these oncologic cases.
Methods
Patient database and examined prognostic systems
The patient cohort for the analysis was compiled from the electronic medical record at the
National  Institute  of  Clinical  Neuroscience,  in  Budapest,  Hungary.  We  identified  382
operations in 337 patients who underwent surgery because of vertebral metastasis, and we had
information about the date of last surgery for 329 patients. The operations were performed
from December 2007 to December 2015. The status of the patient or the date of death was
checked  in  December  2016.  The  only  inclusion  criterion  was  a  positive  diagnosis  with
metastatic spinal lesions and surgical treatment of the lesions. Some of the patients (n 1⁄4 38)
had more than 1 surgical intervention (31 patients with 2 interventions and 7 patients with 3
interventions; none of the patients had >3 interventions). 
The 4 examined scoring systems were the following:
 Tokuhashi et al. [12-16] reported a scoring system in 1989, and after 16 years, in
2005, the same group reported a revised version (Table 1).
 The system by Tomita and Kawahara [17] was constructed from a retrospective
analysis in 2001 (Table 2)
 Bauer et al[18].  reported their system in 1995. Later, Leithner et al. [19] and
Wibmer et al. [20] modified the Bauer score, omitting the pathologic fractures as
a risk factor, and they reported better prediction values (Table 3)
 The scoring system by van der Linden et al. [21] was reported in 2005 (Table 4)
We collected all data to score patients by these systems. Demographic and baseline clinical
variables of interest included sex and age at time of surgery. Baseline functional status was
measured by Karnofsky Performance Status. Further data about the status of the patient was
recorded such as main clinical  symptoms, presence of motoric  or sensory deficit,  Frankel
scores, extraspinal bony metastases, and metastases in the internal organs. About the surgical
intervention,  we  extracted  the  following  factors:  affected  vertebral  levels,  steps  of
intervention,  postoperative condition,  and the length of hospital  stay.  Each patient  history
consisted  of  data  about  the  metastasis  (categorized  by primary  site  of  origin),  histologic
diagnoses, and other comorbidities.
Statistical analysis
Survival was calculated from the date of the last operation and either from the date of death or
from the latest follow-up. In cases of death, we had access only to the date, and the cause of
death was not registered in our database. We created survival curves by using a Kaplan-Meier
(KM) formula  and compared them with  a  log-rank test.  P  values  <0.05 were  considered
significant. We calculated the consistency rates (CRs) between the predicted prognosis and
the actual survival in our cohort (1-KM or KM as appropriate) following the definition by
Tokuhashi et al. [15] for the evaluation of predicted survival by the scoring system calculated
from data of the cohort. Calculations were made by R software version 3.0.2 (R Foundation
for Statistical Computing, Vienna, Austria) [22].
Results
Survival and oncologic data of the population
We identified 337 patients, 199 (59.1%) male and 138 (40.9%) female, with a mean age of 63
years (range, 15e88 years). Overall survival (OS) was calculated by the KM formula. Median
OS (amount  of  time  when  50% of  the  patients  have  died)  was  222  days,  and  the  95%
confidence interval (CI) ranged from 175 to 274 days. The prevalence of the most common
primary tumors was distributed as follows: lung (n 1⁄4 84, 24.9%), multiple myeloma (n 1⁄4
38, 11.3%), breast (n 1⁄4 30, 8.9%), cancer of unknown primary site (n 1⁄4 30, 8.9%), kidney
(n 1⁄4 26, 7.7%), prostate (n 1⁄4 22, 5.6%), and colorectal (n 1⁄4 22, 6.5%). Sixty-six patients
had no internal metastasis (19.6%) and 53 had no other skeletal metastasis (15.7%).
Examinations of the prognosis systems
Revised Tokuhashi score
Because  in  the  revised  Tokuhashi  score  (Table  1),  many  tumor  types  with  different
malignancies and prognosis form a group (2 points, “other” category), we had to categorize
our  patients  with  different  primary  tumor  types.  We  sscored  the  patients  according  to
histologic  similarities  and  oncologic  treatment  possibilities  (Table  5).  We  also  used  this
method for the Tomita system (Table 6). The modified Bauer and van der Linden scores did
not need any modification because they are accurate about which types of tumors receive
points and they do not provide examples. We compared the survival of groups of patients in
the  3  prognostic  categories.  We  found  that  these  categories  are  significantly  different
according to survival; the log-rank test reported P < 0.001. We tested each category to check
the deviation from the other 2 categories. Each category was found to be different, but with
various P values: conservative group (0-8 points), P < 0.001; palliative group (9-11 points),
P<0.001; and excisional group (12-15 points), P = 0.013 (Figure 1). We calculated the CRs
for each prognostic category as well (Table 7). The most accurate prediction was observed in
the palliative category, in which the system predicted with 95% CI the real OS time with 57%
to 74% probability.  On average,  the  system predicted  with an  accuracy  of  60.5% in  our
cohort.
Tomita score
We also  had to  make  some specifications  to  the  classification  of  Tomita  primary  tumor
categories (Table 2). Our extended scoring method of Tomita primary tumor categories is
shown in Table 6, which is categorized by histologic similarities  and oncologic treatment
possibilities. The prognostic categories were significantly different according to survival (P <
0.001). We tested all 4 categories separately as well, to establish whether they were different
from the rest of the population. All were significantly different: long-term (2e3 points), P <
0.001; midterm (4e5 points), P 1⁄4 0.007; short-term (6e7 points), P < 0.001; and terminal
(8e10 points), P 1⁄4 0.008. The KM curves are shown in Figure 2. Next, we examined the
accuracy of the predicted survival (Table 8). The CRs in the last column of Table 8 show that
there is a serious difference between our findings and the predicted survival of the Tomita
system.  For  this  cohort,  the  OS was  predicted  correctly  by  this  system with  an  average
accuracy of only 28.8% of the patients, calculated as the average of the last column of Table
8.
Modified Bauer score
This  scoring  system separated  the  cohort  into  significantly  different  groups  (P  <  0.001)
according to OS. Each group was different from the rest of the population as well: the short
survival group (0-1 point), P = 0.0013; moderate survival group (2 points), P < 0.001; and
long survival group (3-4 points), P < 0.001 (see Figure 3 for KM curves). The predictive
value of this system is  shown in Table 9.  This system could not be regarded as accurate
(29.5% of global prediction ability), especially for the moderate group, which resulted in a
low CR. OS was predicted correctly for only 6.3% of the patients with a modified Bauer score
of 2.
Van der Linden score
This system was the only one in which the prognostic groups were not significantly different
(Figure 4). We examined the prediction ability of this system as well (Table 10). Although the
van der Linden system did not separate groups of patients with significantly different KM
curves, its average prediction ability (48.6%) is better than that of the modified Bauer and
Tomita values.
Discussion
Scoring systems were introduced in neurosurgical practice to determine the best treatment
decisions in metastatic spinal diseases. The aim of our study was to compare 4 well-known
systems and analyze them to identify which presents the best prediction results.
The revised Tokuhashi scoring system [15] (Table 1) is widely used in clinical practice and
receives much attention. In a restricted cohort of patients with only hepatocellular carcinoma,
Chen et al. [23] also compared the predictive ability of the 4 scoring systems. The main result
of their study agrees with that of the present analysis: the revised Tokuhashi system has the
best ability to predict survival (Figure 1). However, there are notable variances among the
exact performances of the revised Tokuhashi scores in the literature. When Tokuhashi et al.
[16]  investigated  the  ability  of  their  system,  they  found  an  88%  predictive  probability,
Yamashita  et  al.  [24]  reported  79%,  and  Hessler  et  al.  [25]  reported  67%,  when  the
calculations  were  based  on  cohorts  of  <100  patients.  Eap  at  al.  [26]  reported  the
reproducibility and usefulness of the system in a 260-patient population and found a weighted
Cohen k coefficient  of 0.41 (95% CI,  0.33-0.50).  Our results  confirm the findings  in  the
literature.  For the conservative category, the survival for 62% of the patients matched the
prediction  of  the  system,  for  the  palliative  category,  this  value  was  65%,  and  for  the
excisional group, it was 54%. On average, the system has 60.8% predicting ability. This value
is near the mean in the literature (i.e., 66%).[27-29] We found also that the scoring system
separates the groups of patients with different prognosis with a very strong significance, and
the conservative category was most significantly separated from the rest of the population
(Table 7).
Bauer et al.  [30] showed that the Tomita scoring system (Table 2) separates patients into
groups with good and bad prognosis. We found similar results by showing that the survival
curves  of  the  categories  of  the Tomita  system are  significantly  different  from each other
(Figure 2). The most separated group was the one with patients with long-term prognosis
(Table 8). According to our calculations, the Tomita system predicted the survival of patients
in our cohort with a low probability (28.8%). The analysis of the modified Bauer score 18
(Table 3) also affirms the findings in the literature. The prognostic groups of this system were
significantly different (Figure 3) and 2 groups (the good and the moderate) were significantly
different from the rest of the population (Table 9). We calculated the predictive ability of the
Bauer system as well and found a low value (29.5%).
van der Linden et al. [21] examined their own van der Linden system (Table 4) and reported a
73% predictive  probability.  In  the  cohort  in  our  study,  the van der  Linden score did not
achieve  such  high  results  (48.6%).  Furthermore,  we  did  not  find  significant  differences
between the survival curves of the groups of this system (Figure 4, Table 10).
The scoring systems have their own errors and pitfalls, [7,11,25,31,32] but they are widely
accepted  in  clinical  practice.  [7,11,24,26,27,33-36]  The  results  are  shown  in  Table  11.
Examination of our population showed that the revised Tokuhashi system performs the best
prediction results and the results of other prognostic systems (Tomita system and modified
Bauer  system but  not  the  van  der  Linden  score)  are  also  in  accordance  with  previously
reported findings. However, this study is limited by its retrospective design and usually there
are large variations in intervention responses because of unrecorded genetic,  habitual,  and
personal  features  of  patients  that  can  modify  the  results;  therefore,  the  conclusion  and
consequences must be cautiously considered. To the best of our knowledge, there are no any
bigger single-center studies in the literature, so we hope that our research will contribute to
knowledge about prognosis predicting scoring systems.
Conclusion
The aim of this article was to analyze 4 prognostic scoring systems of patients with
spinal metastasis and determine which presents the best prediction results. 
According  to  our  findings,  the  Tomita  and  Bauer  scores  separated  the  classes  of
patients  with good and moderate  prognosis,  and patients  with poor condition  were easily
identified with the revised Tokuhashi scoring system. Concerning the ability of predicting
average survival, the revised Tokuhashi system was the most reliable. However, we found
considerable differences between the predictive values of the scoring systems compared with
results in the literature. 
Spinal metastatic diseases remain a serious and challenging surgical problem, but early
diagnosis  and  sufficient  treatment  may  prevent  serious  complications  and  allow  longer
survival. Using reliable prognostic scoring systems, the surgical decision can be determined
more  precisely.  We  believe  that  our  results  could  be  a  possible  base  for  multicentric
prospective  study in the  future to  determine  the  best  treatment  protocol  for  patients  with
spinal metastases.
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Tables
Table 1. The Revised Tokuhashi Score
Predictive Factors Point(s)
General  condition  (Karnofsky
Performance Status, %)
Poor (10-40) 0
Moderate (50-70) 1
Good (80-100) 2
Number of extraspinal bone foci
>=3  0
1-2  1
0 2
Number  of  metastases  in  the
vertebral body
>=3  0
2 1
1 2
Metastasis  to  the  major  internal
organs
Nonremovable 0
Removable 1
No metastasis 2
Primary site of the cancer
Lung,  osteosarcoma,  stomach,
bladder, esophagus, pancreas
 0
Liver, gallbladder, unidentified  1
Others 2
Kidney, uterus 3
Predictive Factors Point(s)
Rectum 4
Thyroid, breast, prostate, arcinoid 5
Palsy
Frankel A, B (complete) 0
Frankel C, D (incomplete) 1
Frankel E (none) 2
Prognostic Categories (Points) Interpretation
0-8 85%  lives  <6  months  -->  conservative
treatment or palliative surgery
9-11 73% lives >6 months (and 30% >1 year)--
>  palliative  surgery  or  (exceptionally)
excisional surgery
12-15 95% lives >1 year --> excisional surgery
Table 2 The Tomita Score
Predictive Factors Point(s)
Primary tumor
Slow growth (e.g., breast, prostate, thyroid) 1
Moderate growth (e.g., kidney, uterus) 2
Rapid  growth  (e.g.,  lung,  liver,  stomach,
colon, primary unknown)
4
Primary tumor
No visceral metastasis 0
Treatable 2
Untreatable  4
Bone metastasis (including spine)
Solitary/isolated 1
Multiple 2
Prognostic Categories (Points) Interpretation
2-3 Long-term  local  control  (mean
survival  50  months)  -->  wide  or
marginal excision
4-5 Mid-term  local  control  (mean
survival 23.5 months) --> marginal
or intralesional excision
6-7 Short-term  palliation  (mean
survival  15  months)  --> palliative
surgery
8-10 Terminal  care  (mean  survival  6
months)  -->  supportive  care,  no
surgery
Table 3. The Modified Bauer Score
Predictive Factors Point(s)
No visceral metastasis 1
No lung cancer 1
Primary  tumor  =  breast,  kidney,
lymphoma, multiple myeloma
1
1 solitary skeletal metastasis 1
Prognostic Categories (Points) Interpretation
0-1  4.8 monthsesupportive care, no surgery
2 18.2  monthseshort-term  palliation,  dorsal
surgery
3-4 28.4  monthsemid-term  local  control,
dorsoventral surgery
Table 4 The van der Linden Score
Predictive Factors Point(s)
Karnofsky Performance Status
80-100  2
50-70 1
20-40 0
Primary tumor
Breast 3
Prostate 2
Lung 1
Other  0
Visceral metastasis
No 1
Yes 0
Prognostic Categories (Points) Interpretation
0-3 4.8 monthseconservative therapy
4-5 13.1 monthsepalliative surgery
6 18.3 monthseexcisional surgery
Table  5.  Extended  Scoring  Method  for  Revised  Tokuhashi  Primary  Tumor
Categories
Points Primary Site of Cancer (Revised Tokuhashi)
0 Lung,  osteosarcoma,  chondrosarcoma,  stomach,  bladder,  esophagus,
pancreas,  angiosarcoma,  melanoma,  mesothelioma,  neuroendocrine
carcinoma
1 Liver, gallbladder, unidentified
2 Others, germ cell tumors, other epithelial carcinomas (e.g., tonsils and
larynx), hematologic malignancies, parotis 
3 Kidney, uterus, cervix, ovarium
4 Colon, rectum
5 Thyroid, breast, prostate, carcinoid tumor, osteoblastoma, chondroma,
hemangioma
Table 6. Extended Scoring Method for Tomita Primary Tumor Categories
Points Primary Tumor (Tomita)
1 Slow  growth  (e.g.,  breast,  prostate,  thyroid,  osteoblastoma,
chondroma, hemangioma)
2 Moderate growth (e.g., kidney, uterus, cervix, germ cell  tumors,
other epithelial carcinomas [e.g., tonsils and larynx], hematologic
malignancies, parotis) 
4 Rapid growth (e.g.,  lung,  liver,  stomach,  colon,  rectum, primary
unknown,  osteosarcoma,  chondrosarcoma,  extraskeletal  Ewing
sarcoma,  giant  cell  bone  tumor,  angiosarcoma,  gallbladder
carcinoma,  bladder  carcinoma,  melanoma,  mesothelioma,
pancreas, neuroendocrine carcinoma, esophagus) 
Table 7. Predictive Values of the Revised Tokuhashi System, KM=Kaplan-Meier
Point Category (Points) Prognosis
(days) 
Number  of
Patients
Consistency Rate (1-KM or KM)
(95% Confidence Interval)
Conservative (0-8)  <180   138  1-KM: 0.62 (0.529e0.693)
Palliative (9-11) >180  127 KM: 0.653 (0.575-0.741)
Excisional (12-15) >365  59  KM: 0.541 (0.422-0.693)
Table 8. Predictive Values of the Tomita System
Point 
Category
Prognosis 
(days)
Number of 
Patients
 Consistency Rate (Kaplan-Meier) 
(95% Confidence Interval)
2-3 >50 x 30 97 0.414 (0.313-0.549)
4-5 >23.5 x 30 105 0.153 (0.093-0.252)
6-7 >15 x 30 84 0.190 (0.120-0.301)
8-10 >6 x 30 41 0.394 (0.266-0.584)
Table 9. Predictive Values of the Modified Bauer System
Point
Category 
Prognosis
(days) 
Number  of
Patients 
Consistency  Rate  (Kaplan-Meier)
(95% Confidence Interval)
0-1 >4.8 x 30 26 0.461 (0.305-0.699)
 2 >18.2 x 30 108 0.063 (0.029-0.136)
 3-4 >28.4 x 30 195 0.363 (0.295e0.446)
Table 10. Predictive Values of the van der Linden System
Point
Category 
Prognosis
(days) 
Number  of
Patients 
Consistency  Rate  (Kaplan-Meier)
(95% Confidence Interval)
0-3 >4.8 x 30 263 0.595 (0.539-0.658)
4-5 >13.1 x 30 54 0.407 (0.295-0.562)
6 >18.3 x 30 11 0.455 (0.212-0.973)
Table 11. Evaluation of the Scoring Systems According to the Literature
Reference Publicati
on Date 
Type of
Study
Number of Cases/
Number of Articles
Identified
Investigate
d Systems
Conclusion
Zoccali  et
al. [7] 
April
2015 
Review 1686/— Revised
Tokuhashi 
The  mean
predicting  ability
is  63%.  It  needs
critical
assessment,
especially  of
patients  with  12
months survival
Tokuhashi
et al. [11]
July 2014 Review —/236 Tokuhashi,
revised
Tokuhashi,
Tomita,
Bauer, van
der
Linden,
Rades,
Katagiri 
Effectiveness  and
pitfalls  of  all  of
these  systems
discussed
Yamashit
a  et  al.
[24] 
May
2011 
Prospec
tive  
85/—  Revised
Tokuhashi 
79%  of  mean
predicting ability
Hessler et
al. [25] 
May
2011 
Retrosp
ective 
81/— Revised
Tokuhashi 
67.1%  of  mean
predicting ability
Eap et al.
[26]
March
2015 
Retrosp
ective 
260/— Revised
Tokuhashi 
They  confirm  the
validity  of  the
system
Luksanapr
uksa et al.
[27]  
May
2017 
Review
and
meta-
analysi
s 
—/3959 Revised
Tokuhashi,
Tomita,
Bauer, van
der Linden
Effectiveness  and
pitfalls  of  all  of
these  systems
discussed
Reference Publicati
on Date 
Type of
Study
Number of Cases/
Number of Articles
Identified
Investigate
d Systems
Conclusion
Oliveira et
al. [31]
 July
2013 
Prospec
tive 
60/— Revised
Tokuhashi 
The system is not
useful  in  guiding
treatment
Gakhar  et
al. [32] 
August
2013 
Prospec
tive 
90/— Revised
Tokuhashi 
Only  33.4%  of
mean  survival
predictability
reported
Papastefa
nou et al.
[33]
2012 Prospec
tive 
52/— Revised
Tokuhashi,
Tomita 
The  Tokuhashi
score  is  more
valuable than the
Tomita score
Wang  et
al. [34] 
April
2012 
Prospec
tive 
448/— Tokuhashi
and
revised
Tokuhashi 
Both  of  the
systems  showed
significant
predictive value 
Aoude  et
al. [35] 
June
2014 
Retrosp
ective 
128/— Revised
Tokuhashi,
Tomita  
Both  of  the
systems  are
useable,  but  the
Tokuhashi system
has  better
accuracy
Petteys et
al. [36] 
March
2015 
Retrosp
ective 
30/— Revised
Tokuhashi 
The  Tokuhashi
score  can  be
useful
